A San Diego biotech has set out to solve the formula for best-in-class antibody-drug conjugates, raising $120 million with support from Big Pharma Merck & Co. to fuel its efforts. Solve Therapeutics’ ...
Protein‐polymer conjugates represent a dynamic class of hybrid materials that combine the inherent biological function and specificity of proteins with the versatile properties of synthetic polymers.